Characteristics of RM Dosimetry Patients
| Patient no. | Sex | Age (y) | Dose (MBq/kg) | Injected activity (MBq) | Pretreatment/predosing* | Baseline thrombocytes (109/L) | Baseline neutrophils (109/L) | Prior treatment |
| 1 | F | 58 | 10 | 1,102 | R | 345 | 4.5 | R×4; R-CHOP×2 plus CHOP×4 |
| 13 | M | 72 | 15 | 1,416 | R | 198 | 2.1 | R-CVP×6; R-bendamustin×6 |
| 14 | F | 70 | 15 | 1,013 | R | 243 | 2.8 | EBRT, 30 Gy; R×4; R-bendamustin×6; R-CHOP×6 |
| 15 | M | 68 | 10 | 1,130 | R | 206 | 3.6 | R-CHOP×6 |
| 2 | M | 58 | 10 | 1,036 | R + lilotomab | 233 | 2.6 | R×8; R×4; chlorambucil×6; R-CHOP×6; EBRT, 30 Gy; R-bendamustin×6; R×2 |
| 3 | M | 50 | 10 | 746 | R + lilotomab | 339 | 7 | Chlorambucil×3; EBRT, 30 Gy; R-galiximab×6; R-CHOP×6; R maintenance |
| 9 | M | 65 | 15 | 1,696 | R + lilotomab | 298 | 6.8 | R×4 |
| 12 | F | 49 | 15 | 1,015 | R + lilotomab | 268 | 3.1 | Intratumoral R with dendritic cells×3 plus EBRT, 8 Gy; intratumoral R with dendritic cells×2 plus EBRT, 8 Gy; R×4; R-bendamustin×1 |
↵* R refers to pretreatment with rituximab; lilotomab refers to predosing with unlabeled antibody.
R = rituximab; CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP = cyclophosphamide, vincristine and prednisone; EBRT = external-beam radiotherapy.